Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 498 (1 June 2009) | doi:10.1038/nbt0609-498b
India's first true stem cell trials
Abstract
The Drug-Controller General of India (DCGI) has given the go-ahead for the first clinical trials designed to test stem cell products. Stempeutics Research of Bangalore launched a combined phase 1 and phase 2 trial on April 22 to evaluate whether its stem cell products can benefit people who have experienced myocardial infarction and individuals with critical limb ischemia (CLI)—a condition that often requires amputation.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
